APA (7th ed.) Citation

Ackroyd, J., Deodhar, S. S., Loganathan, S., Singh, G., Marwah, A., Kumar, K., . . . Athalye, S. N. (2025). Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon's ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: Results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1). Expert opinion on investigational drugs, 34(4), 349. https://doi.org/10.1080/13543784.2025.2500334

Chicago Style (17th ed.) Citation

Ackroyd, Jonathan, Sarika S. Deodhar, Subramanian Loganathan, Gursharan Singh, Ashwani Marwah, Kuldeep Kumar, Jayanti Panda, and Sandeep Nilkanth Athalye. "Pharmacokinetic Equivalence and Comparative Safety, Tolerability, and Immunogenicity of Biocon's Ustekinumab (Bmab-1200) with EU-approved and US-licensed Reference Ustekinumab in Healthy Subjects: Results from the Study to Test Pharmacokinetic BioEquivalence of BiosimiLar Ustekinumab to SteLARa (STELLAR-1)." Expert Opinion on Investigational Drugs 34, no. 4 (2025): 349. https://doi.org/10.1080/13543784.2025.2500334.

MLA (9th ed.) Citation

Ackroyd, Jonathan, et al. "Pharmacokinetic Equivalence and Comparative Safety, Tolerability, and Immunogenicity of Biocon's Ustekinumab (Bmab-1200) with EU-approved and US-licensed Reference Ustekinumab in Healthy Subjects: Results from the Study to Test Pharmacokinetic BioEquivalence of BiosimiLar Ustekinumab to SteLARa (STELLAR-1)." Expert Opinion on Investigational Drugs, vol. 34, no. 4, 2025, p. 349, https://doi.org/10.1080/13543784.2025.2500334.